For laboratory research use only. Not for human consumption.

What Is Melanotan II?

Melanotan II is a synthetic analog of alpha-melanocyte stimulating hormone, originally developed at the University of Arizona. It activates multiple melanocortin receptors — MC1R through MC5R — making it one of the broadest-acting melanocortin agonists in the research literature. Its development led directly to the discovery of PT-141, making it a foundational compound in melanocortin receptor pharmacology.

Short Answer

Melanotan II is a cyclic peptide that activates the melanocortin receptor family, with particular affinity for MC1R (involved in melanogenesis) and MC4R. Developed as a research tool for studying melanocortin pathways, it has been the subject of published studies examining receptor binding profiles, dose-dependent melanin production, and pharmacokinetic properties. Its broad receptor activity profile makes it valuable for studying how the melanocortin system operates across multiple receptor subtypes simultaneously.

Research Areas

Key areas of investigation documented in the published literature.

Melanocortin Receptor Pharmacology

The melanocortin receptor system consists of five receptor subtypes (MC1R through MC5R), each expressed in different tissues and involved in different biological processes. Research at the University of Arizona documented that Melanotan II activates all five subtypes, with particularly strong affinity for MC1R and MC4R. This broad activity profile distinguishes it from more selective agonists like PT-141, and makes it a research tool for studying how different melanocortin receptors interact and influence each other within the same signaling network.

Pigmentation Pathway Research

MC1R activation is the primary pathway through which melanocortin signaling influences melanogenesis — the production of melanin pigment. Published studies have documented dose-dependent increases in melanin production following Melanotan II administration in research settings. This line of investigation has been important for understanding the molecular mechanisms that regulate pigmentation at the receptor level, and for mapping the signaling cascade from receptor activation through to melanin synthesis in melanocytes.

Connection to PT-141 Research

During Melanotan II clinical studies in the late 1990s, researchers observed unexpected physiological responses mediated through MC3R and MC4R rather than the pigmentation pathway they were studying. This serendipitous observation led directly to the development of PT-141 (Bremelanotide) as a more selective melanocortin agonist. The Melanotan II research program therefore serves as an important case study in how broad-spectrum receptor research can lead to the identification of more targeted compounds for specific pathway investigation.

Explore the Research

Dive deeper into the published literature and compound profiles.

For laboratory research use only. This content is provided for educational purposes about ongoing scientific research. Not for human consumption.